undamentalytics Newsletter
Sign in

Anaptysbio, Inc income statement

In fiscal 2025, Anaptysbio, Inc reported revenue of $235m, up 157.0% on the year before, operating income of $227m (a 96.7% margin) and net income of −$13.2m, or −$0.44 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue181710587563101791235238
Research and development1715295699809889132164136—
General and administrative449161619213742141110
Operating income−3−3−29−67−107−24−57−115−16466227313
Interest expense0022100—————
Income before tax−5−4−30−62−97−20−58−129−16431162235
Income tax000−0−0000−001−181
Net income−5−4−30−62−97−20−58−129−164−145−13196
Diluted EPS−$2.12−$1.62−$1.52−$2.50−$3.60−$0.73−$2.11−$4.57−$6.08−$4.92−$0.44—
Diluted shares (average)3m3m20m25m27m27m27m28m27m30m30m—
EBITDA−3−3−29−66−107−23−56−114−16466227313

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANAB vs RYTMANAB vs IDYAANAB vs PBYIANAB vs LGND

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anaptysbio, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anaptysbio, Inc.